Tekla Capital Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Tekla Capital Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,473,710	Closed	-$1.02M	–	226
2020 Q4	$1.02M	Hold	1,473,710	–	–	0.04%	178
2020 Q3	$3.32M	Hold	1,473,710	–	–	0.12%	121
2020 Q2	$5.28M	Hold	1,473,710	–	–	0.2%	98
2020 Q1	$5.6M	Hold	1,473,710	–	–	0.25%	77
2019 Q4	$4.44M	Buy	+1,473,710	New	+$3.83M	0.17%	113

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $77B AUM 10.33% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.82B AUM

WAM

Westport Asset Management Southport, Connecticut $245M AUM 15.03% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Tekla Capital Management's BMY.RT Position: Q1 2021 in Review

Tekla Capital Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 1,473,710 shares — an estimated $1.02M sold.

Tekla Capital Management first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $5.6M in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Tekla Capital Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Tekla Capital Management sold 1,473,710 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $1.02M.
Tekla Capital Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
Tekla Capital Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $5.6M in Q1 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Tekla Capital Management's 13F filing for Q1 2021, filed 14 May 2021.